PTJ
BRNS

Paul Tudor Jones’s Barinthus Biotherapeutics BRNS Stock Holding History

Paul Tudor Jones’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-266,927
Closed -$1.19M – 2320
2022
Q2 		$1.19M Buy
+266,927
New +$1.29M 0.03% 788
2021
Q4 		– Sell
-378,260
Closed -$5.73M – 2417
2021
Q3 		$5.73M Sell
378,260
-42,059
-10% -$639K 0.09% 226
2021
Q2 		$6.01M Buy
+420,319
New +$6.22M 0.11% 164

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paul Tudor Jones's BRNS Position: Q3 2022 in Review

Paul Tudor Jones sold out of Barinthus Biotherapeutics (BRNS) in Q3 2022, closing a stake of 266,927 shares — an estimated $1.19M sold.

Paul Tudor Jones first reported a position in BRNS in Q2 2021 and held it in 3 quarters. The position peaked at $6.01M in Q2 2021. 11 funds tracked by Wall St. Rank hold BRNS as of Q3 2022.

  • Paul Tudor Jones reported no remaining Barinthus Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Paul Tudor Jones sold 266,927 Barinthus Biotherapeutics shares in Q3 2022, an estimated $1.19M.
  • Paul Tudor Jones first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 3 quarters.
  • Paul Tudor Jones's Barinthus Biotherapeutics position peaked at $6.01M in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2022.

Based on Tudor Investment Corp's 13F filing for Q3 2022, filed 14 Nov 2022.